OXFORD, UK--Oxford GlycoSciences last month appointed Andrew Lyall to the position of chief information officer. Lyall formerly led research efforts in bioinformatics at Glaxo Wellcome as its head of advanced technology and informatics. At Glyco-Sciences he will be responsible for leading and expanding bioinformatics activities. Lyall holds a doctorate in bioinformatics from the University of Edinburgh and serves on a number of UK and international government and academic committees dealing with the emerging issues of bioinformatics and scientific computing.
GlycoSciences' CEO Michael Kranda remarked that "drug discovery, development, and commercialization are being transformed by new data- intensive technologies such as genomics and proteomics. But managing the data explosion and mining it for new therapeutic opportunities and diagnostics has resulted in a bottleneck which requires the development of advanced bioinformatics." Kranda added that he believes Lyall's expertise provides GlycoSciences with a competitive advantage as the company exploits its proteomics technology platform.